RxDoctor Payments Data

Emily Wolf

Nurse Practitioner · Neenah, WINPI 1720739543

Payments from drug & device makers

$1,161in general payments, 2019–2025

Across 44 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$136
  • AbbVie$129
  • Bioventus LLC$105
  • Immunitybio, Inc.$104
  • Sumitomo Pharma America, Inc.$75
  • Merck$70
  • plus $541 from 16 others

What the payments were for

  • Food & beverage$1,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,161 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$299,469
Medicare patients
348
Services billed
3,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron150$88,012
MyrbetriqMirabegron110$82,095
Mirabegron ErMirabegron16$8,179
Tamsulosin Hcl458$7,402
Methenamine Hippurate61$3,873
Solifenacin Succinate117$3,080
Estradiol32$2,829
Trospium Chloride31$2,019
Trospium Chloride ErTrospium Chloride12$1,765
Finasteride161$1,662
Oxybutynin Chloride ErOxybutynin Chloride89$1,603
Testosterone12$1,537
Fesoterodine Fumarate ErFesoterodine Fumarate23$1,106
Potassium Citrate ErPotassium Citrate12$1,063
Terazosin Hcl39$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$75$88,012150 claims
Astellas Pharma US IncMyrbetriq$67$82,095110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Neenah

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →